NASDAQ:AGIO Agios Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $25.01 +1.65 (+7.06%) (As of 07/5/2022 02:52 PM ET) Add Compare Share Today's Range$22.75▼$25.1050-Day Range$17.06▼$24.1452-Week Range$16.75▼$58.61Volume22,333 shsAverage Volume868,415 shsMarket Capitalization$1.37 billionP/E RatioN/ADividend YieldN/APrice Target$50.57 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Agios Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside113.8% Upside$50.57 Price TargetShort InterestBearish12.62% of Float Sold ShortDividend StrengthN/ASustainability-1.09Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($7.02) to ($6.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.05 out of 5 starsMedical Sector310th out of 1,428 stocksPharmaceutical Preparations Industry146th out of 680 stocks 3.3 Analyst's Opinion Consensus RatingAgios Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.57, Agios Pharmaceuticals has a forecasted upside of 113.8% from its current price of $23.65.Amount of Analyst CoverageAgios Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.62% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Agios Pharmaceuticals has recently decreased by 1.68%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgios Pharmaceuticals has received a 69.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agios Pharmaceuticals is -1.09. Previous Next 2.2 News and Social Media Coverage News SentimentAgios Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Agios Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.48% of the stock of Agios Pharmaceuticals is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($7.02) to ($6.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Agios Pharmaceuticals (NASDAQ:AGIO) StockAgios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More AGIO Stock News HeadlinesJune 25, 2022 | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Shares Up 10.1%June 19, 2022 | seekingalpha.comAgios Pharmaceuticals (AGIO) Presents At EHA 2022 Conference - SlideshowJune 15, 2022 | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Hits New 1-Year Low at $17.62June 13, 2022 | finance.yahoo.comCENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood DiseaseJune 10, 2022 | finance.yahoo.comAgios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual CongressMay 17, 2022 | finance.yahoo.comAgios Is Looking For Development Partner, Lays Off Exploratory Research StaffMay 17, 2022 | seekingalpha.comAgios chief scientific officer to depart amid layoffs as company pivots to genetic diseasesMay 17, 2022 | markets.businessinsider.com7 Analysts Have This to Say About Agios PharmaceuticalsMay 16, 2022 | msn.comCambridge biotech Agios to cut more than 10 percent of its workforceMay 16, 2022 | finance.yahoo.comAgios Announces Evolution of Research OrganizationMay 16, 2022 | finance.yahoo.comAgios to lay off 50 as it sets its sights on later-stage drugsMay 12, 2022 | finance.yahoo.comAgios to Present Clinical and Translational Data at the European Hematology Association Annual CongressMay 10, 2022 | seekingalpha.comAgios: Approved Product, Upcoming CatalystsMay 10, 2022 | finance.yahoo.comAgios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022May 5, 2022 | ca.investing.comAgios Pharma Tops Q1 EPS by 7cMay 5, 2022 | finance.yahoo.comAgios Reports Business Highlights and First Quarter 2022 Financial ResultsMay 5, 2022 | seekingalpha.comAgios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q1 2022 Results - Earnings Call TranscriptMay 4, 2022 | seekingalpha.comAgios Pharmaceuticals Q1 2022 Earnings PreviewMay 2, 2022 | nasdaq.comComparing Bitcoin Versus Agios Pharmaceuticals Reveals New LowApril 21, 2022 | finance.yahoo.comAgios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022April 14, 2022 | finance.yahoo.comAgios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase DeficiencyMarch 11, 2022 | markets.businessinsider.comAccord BioPharma Announces New Executive Leadership in Commercialization and MarketingFebruary 28, 2022 | finance.yahoo.comAgios to Participate in March Investor ConferencesFebruary 24, 2022 | benzinga.comHC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $96February 24, 2022 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About Agios PharmaceuticalsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGIO CUSIPN/A CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees390Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today7/05/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$50.57 High Stock Price Forecast$96.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+102.2%Consensus RatingModerate Buy Rating Score (0-4)2.57142857142857 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($6.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$1.60 billion Net MarginsN/A Pretax Margin-43,318.15% Return on Equity-25.67% Return on Assets-23.29% Debt Debt-to-Equity RatioN/A Current Ratio21.30 Quick Ratio21.24 Sales & Book Value Annual Sales$203.20 million Price / Sales6.74 Cash FlowN/A Price / Cash FlowN/A Book Value$23.79 per share Price / Book1.05Miscellaneous Outstanding Shares54,790,000Free Float52,334,000Market Cap$1.37 billion OptionableOptionable Beta1.34 Agios Pharmaceuticals Frequently Asked Questions Should I buy or sell Agios Pharmaceuticals stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Agios Pharmaceuticals stock. View analyst ratings for Agios Pharmaceuticals or view top-rated stocks. What is Agios Pharmaceuticals' stock price forecast for 2022? 7 Wall Street analysts have issued 12 month target prices for Agios Pharmaceuticals' stock. Their AGIO stock forecasts range from $16.00 to $96.00. On average, they predict Agios Pharmaceuticals' stock price to reach $50.57 in the next twelve months. This suggests a possible upside of 102.9% from the stock's current price. View analysts' price targets for Agios Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Agios Pharmaceuticals' stock performed in 2022? Agios Pharmaceuticals' stock was trading at $32.87 at the beginning of 2022. Since then, AGIO shares have decreased by 24.2% and is now trading at $24.93. View the best growth stocks for 2022 here. When is Agios Pharmaceuticals' next earnings date? Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Agios Pharmaceuticals. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.85) by $0.11. The biopharmaceutical company had revenue of $0.83 million for the quarter, compared to the consensus estimate of $2.71 million. During the same quarter last year, the company earned ($1.31) EPS. View Agios Pharmaceuticals' earnings history. Who are Agios Pharmaceuticals' key executives? Agios Pharmaceuticals' management team includes the following people: Dr. Jacqualyn A. Fouse Ph.D., CEO & Director (Age 61, Pay $1.32M)Mr. Jonathan Biller J.D., CFO & Head of Corp. Affairs (Age 57, Pay $804.18k)Dr. Bruce Car Ph.D., Exec. Officer (Age 60, Pay $776.12k)Dr. Sarah Gheuens M.D., Ph.D., Chief Medical Officer (Age 42, Pay $1.57M)Ms. Richa Poddar, Chief Commercial Officer (Age 40, Pay $624.08k)Dr. Lewis Clayton Cantley Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 73)Dr. Tak Wah Mak, Co-Founder & Member of Scientific Advisory Board (Age 76)Dr. Craig B. Thompson, Co-Founder & Chairman of Scientific Advisory Board (Age 69)Dr. Shin-San Su Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 66)Mr. T. J. Washburn Jr., Principal Accounting Officer (Age 41) What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO? 11 employees have rated Agios Pharmaceuticals CEO Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among Agios Pharmaceuticals' employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Agios Pharmaceuticals' key competitors? Some companies that are related to Agios Pharmaceuticals include Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Intra-Cellular Therapies (ITCI), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Hypera (HYPMY), Ultragenyx Pharmaceutical (RARE), Cerevel Therapeutics (CERE), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Mirati Therapeutics (MRTX), Karuna Therapeutics (KRTX) and Galapagos (GLPG). View all of AGIO's competitors. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX). What is Agios Pharmaceuticals' stock symbol? Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO." How do I buy shares of Agios Pharmaceuticals? Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Agios Pharmaceuticals' stock price today? One share of AGIO stock can currently be purchased for approximately $24.93. How much money does Agios Pharmaceuticals make? Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.37 billion and generates $203.20 million in revenue each year. The biopharmaceutical company earns $1.60 billion in net income (profit) each year or ($6.45) on an earnings per share basis. How many employees does Agios Pharmaceuticals have? Agios Pharmaceuticals employs 390 workers across the globe. How can I contact Agios Pharmaceuticals? Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for Agios Pharmaceuticals is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com. This page (NASDAQ:AGIO) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
